Biltmore Capital Advisors’s Pfizer PFE Stock Holding History

Biltmore Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$432K	Sell	7,323 -636	-8%	-$31.5K	0.07%	94
2021 Q3	$342K	Sell	7,959 -1,538	-16%	-$68.1K	0.06%	105
2021 Q2	$372K	Buy	9,497 +772	+9%	+$30K	0.07%	89
2021 Q1	$316K	Buy	+8,725	New	+$310K	0.07%	99

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Biltmore Capital Advisors's PFE Position: Q4 2021 in Review

Biltmore Capital Advisors reduced its Pfizer (PFE) stake by 8% in Q4 2021, selling an estimated $31.5K and leaving 7,323 shares worth $432K. The position accounts for 0.07% of the portfolio, ranked #94.

Biltmore Capital Advisors first reported a position in PFE in Q1 2021 and has held it in 4 quarters since. 3,262 funds tracked by Wall St. Rank hold PFE as of Q4 2021.

Biltmore Capital Advisors held 7,323 shares of Pfizer worth $432K as of Q4 2021.
Biltmore Capital Advisors sold 636 Pfizer shares in Q4 2021, an estimated $31.5K.
Pfizer made up 0.07% of Biltmore Capital Advisors's portfolio in Q4 2021, its #94 holding.
Biltmore Capital Advisors first reported a position in Pfizer in Q1 2021 and has held it in 4 quarters since.
3,262 funds tracked by Wall St. Rank held Pfizer as of Q4 2021.

Based on Biltmore Capital Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.